With a new U.S. administration in place, regulatory scrutiny is intensifying. From shifting energy policies to AI-driven compliance risks, global enforcement authorities are cracking down – demanding greater transparency, accountability, and resilience across sectors. Life sciences companies face growing risks. Heightened oversight of AI, lobbying, and patient organization funding is changing how businesses manage compliance. Partners Calvin Ding, Gejaa Gobena, and Désirée Maier break down the latest global enforcement priorities and their impact in Reuters’ Westlaw Today:?https://lnkd.in/dH8Ck7fD Despite a pivot away from dedicated investment in renewables by the new presidential administration, the trend in increased enforcement of renewable energy-related fraud may likely continue, particularly given the administration’s focus on domestic fossil fuel production. Partners Anne Carpenter and Nadira Clarke analyze the latest trends and what they mean for the sector:?https://lnkd.in/dXKXVFVW This is just the beginning. Across sectors, authorities are prioritizing enforcement – and businesses must adapt. Stay ahead of key regulatory shifts in our Global Bribery & Corruption Outlook:?https://lnkd.in/ePXR8YsV #Regulation #Compliance #Fraud #RenewableEnergy #Energy #LifeSciences
